We enjoyed this read on @LongevityTech featuring LongevityTech.Fund Founder @PetrSramekBench who compares today’s longevity investment market to the AI sector before valuations skyrocketed.

We're happy to see that @WashingtonPost is discussing the continued rise in centenarians with such a large audience. At Oisin, we believe that in addition to environment, lifestyle and location, DNA-targeted genetic intervention can also impact lifespan. wapo.st/40lUVFR

During Longevity Week 2022, @LongevityTech CEO & Founder, Phil Newman emceed an annual masterclass titled "Investing in the Age of Longevity." Read more about the trends we're seeing in the investment space, as well as current challenges here: bit.ly/3FG4rez

Leaving #JPM2023 today feeling invigorated and grateful to have connected with other pioneers in life sciences. It was wonderful to meet in-person and discuss how #longevity can change the healthcare landscape. Thanks @JPMorgan for the amazing experience!

Thanks @Statto for including us in this @WIRED story. It’s exciting to reflect on how far our industry has come, and that "in 2023, early success of these treatments could kickstart the greatest revolution in medicine since the discovery of antibiotics." bit.ly/3Zak85n

Oisín will usher in the New Year at the @JPMorgan Healthcare Conference January 9 - 12. We're eager to connect with other trailblazers in the life sciences space and talk all things #longevity. Feel free to DM us directly if you're interested in setting up a meeting.

Longevity Technology recently sat down with @Dr_Bischof, who argues that the goal of compressing morbidity and maximizing #healthspan needs to be championed by physicians and healthcare systems, with education being at the core. @LongevityTech longevity.technology/news/ed…

Our CEO Matt Scholz recently had the opportunity to sit down with @GailLDutton of @BioSpace to discuss senolytic therapies and their revolutionary potential to prevent diseases of aging, along with a few insights from Oisín studies. Give it a read here: bit.ly/3PuPHCB

According to @McKinsey, the number of older adults will more than double to an estimated 1.6B by mid-century. Despite this, researchers argue that global society has been unsuccessful in extending healthy lifespan and that innovation is key to #aging. bit.ly/3AwcJ5B

Enjoyed this read from @JonathanThon, CEO of @STRMbio, on unlocking the full potential of gene therapies. He mentions that enabling direct injection and precision targeting will result in new, safe treatments and cures for diverse diseases. @_CellandGene bit.ly/3Bcv6gm

Enjoyed tuning into this @lifespanIO presentation following up on EARD. @allisondman, President and Executive Director of @foresightinst, gave a presentation about the Longevity Prize at the August conference. Watch here: bit.ly/3AxHB5P

Last month, @LongevityTech wrote about researchers explaining the pathophysiological links between #longevity and cardiovascular #aging, referencing cellular senescence as a way to promote the secretion of pro-inflammatory molecules. Link here: bit.ly/3gBQmEK

A new study from @UCBerkeley showed that age often plays a larger role than #genetics in gene expression and resistance to future #disease. @LongevityTech bit.ly/3g6DxSs

We’re thrilled about the newly launched Longevity Biotech Fellowship, now accepting applications. Our CEO Matt Scholz is honored to be a mentor within the community, offering guidance to those interested in the revolutionary field of longevity. @LBF_org bit.ly/3ESpppS

Earlier this month, our CEO spoke at @DiscoveryInst1’s #COSM2022 Technology Summit. @cnaintelligence published a great story highlighting the panel discussion, including details on how our technology addresses aging and mitigates harmful side effects. bit.ly/3Gs5nUI

Last month, @ScienceMagazine published a study on aging in mice, which provided insights into determinants of #longevity, highlighting genetic mediators that can be age or sex specific, along with non-genetic effects. Check it out! bit.ly/3ywGqm2